Emiliem Will Use Invitrogen's SelectScreen Tech to Study Cancer Compounds | GenomeWeb
NEW YORK (GenomeWeb News) — Emiliem and Invitrogen will screen Emiliem’s multi-kinase inhibitors under a partnership agreement, the companies said today.
 
The companies said they will use Invitrogen’s SelectScreen for kinase and P450 screening and cellular pathway profiling to study Emiliem’s cancer compounds.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.